US pharma major Bristol-Myers Squibb (NYSE: BMY) has reacquired the rights to ASLAN002 (BMS777607) in China, Australia, Korea, Taiwan and other Asian territories from Aslan Pharmaceuticals.
The Singapore-based, oncology-focused biotech in-licensed ASLAN002, a potent small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint, in these markets from B-MS in November 2011, and has completed a Phase I study of the drug.
It was shown not only to be safe and well-tolerated, but the data also demonstrated that inhibition of RON resulted in potent inhibition of plasma biomarkers of RON activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze